Search research articles
Contact Us
Filters
Showing results (711-720 of 738) with videos related to
Page
of 74
Sort By:
American Journal of Nephrology
|
March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
July 16, 2016
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion
Faiez Zannad, Wendy Gattis Stough, Raymond J Lipicky, et al.
Diabetes, Obesity & Metabolism
|
March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Clare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
European Heart Journal
|
August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Kenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
The New England Journal of Medicine
|
November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
American Journal of Nephrology
|
December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Journal of the American Heart Association
|
August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Jing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Journal of the American College of Cardiology
|
June 3, 2026
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses
Katherine R Tuttle, George L Bakris, Florian M M Baeres, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Tae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
Page
of 74
Search research articles
Search
Showing results (711-720 of 738) with videos related to
Sort By:
Page
of 74
American Journal of Nephrology
|
March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
July 16, 2016
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion
Faiez Zannad, Wendy Gattis Stough, Raymond J Lipicky, et al.
Diabetes, Obesity & Metabolism
|
March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Clare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
European Heart Journal
|
August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Kenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
The New England Journal of Medicine
|
November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
American Journal of Nephrology
|
December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Journal of the American Heart Association
|
August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Jing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Journal of the American College of Cardiology
|
June 3, 2026
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses
Katherine R Tuttle, George L Bakris, Florian M M Baeres, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Tae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
Page
of 74